OREGON CLINICAL AND TRANSLATIONAL RESEARCH INSTITUTE
俄勒冈临床与转化研究所
基本信息
- 批准号:8365044
- 负责人:
- 金额:$ 369.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-07-01 至 2012-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
This subproject represents an estimate of the percentage of the CTSA funding that is
being utilized for a broad area of research (AIDS research, pediatric research, or
clinical trials). The Total Cost listed is only an estimate of the amount of CTSA
infrastructure going towards this area of research, not direct funding provided by
the NCRR grant to the subproject or subproject staff.
DESCRIPTION (provided by applicant): After a successful and highly productive first grant period, the Oregon Clinical and Translational Research Institute (OCTRI) is well positioned to have greater impact in the next grant period. OCTRI's goals are: Specific Aim 1. Generate sustained OHSU and KPCHR research growth and productivity across the spectrum of translational science. Specific Aim 2. Translate new biomedical knowledge into widespread advances in human health and healthcare reform. Specific Aim 3. Create a regional consortium for clinical and translational research. Specific Aim 4. Expand the impact of the strong OCTRI educational curriculum, develop an institution-wide, coordinated career development process that builds on the strengths of existing programs, and extend it throughout the region and nationally. Specific Aim 5. Enhance key infrastructure programs to support local and regional clinical and translational research. These plans will build on major progress during the first grant period to further expand clinical and translational research, career development and benefits to human health. OCTRI will utilize a series of innovative partnerships to leverage CTSA support, expand its extensive collaborations with communities, and take advantage of a regional consortium of academic institutions working together to enhance translation. As a member of the CTSA Consortium, OCTRI will contribute unique expertise and resources to the combined effort to solve biomedical problems. Oregon Health and Science University and its partner institution Kaiser Permanente Center for Health Research have committed strong leadership support and substantial institutional commitment to OCTRI's continued mission.
PUBLIC HEALTH RELEVANCE (provided by applicant): OCTRI will have a major influence on clinical and translational research at OHSU and KPCHR, and will increase their contributions to biomedical discovery. As the only academic medical center in Oregon, OHSU has a unique opportunity to catalyze translational research growth on a regional scale. Via its participation in the CTSA Consortium, OCTRI will advance national research productivity.
该子项目是对CTSA供资的百分比的估计,
用于广泛的研究领域(艾滋病研究,儿科研究,或
临床试验)。 列出的总成本仅为CTSA金额的估算
基础设施走向这一领域的研究,而不是直接提供资金,
向子项目或子项目工作人员提供NCRR补助金。
描述(由申请人提供):经过成功和高效的第一个赠款期,俄勒冈州临床和转化研究所(OCTRI)处于有利地位,在下一个赠款期有更大的影响。OCTRI的目标是:具体目标1。产生持续的OHSU和KPCHR的研究增长和生产力在整个范围内的转化科学。具体目标2。将新的生物医学知识转化为人类健康和医疗改革的广泛进步。具体目标3。创建临床和转化研究区域联盟。具体目标4。扩大强大的OCTRI教育课程的影响,开发一个机构范围内,协调的职业发展过程,建立在现有计划的优势,并将其扩展到整个地区和全国。具体目标5.加强关键基础设施项目,以支持当地和区域临床和转化研究。这些计划将建立在第一个赠款期间取得的重大进展的基础上,以进一步扩大临床和转化研究,职业发展和对人类健康的益处。OCTRI将利用一系列创新的合作伙伴关系来利用CTSA的支持,扩大与社区的广泛合作,并利用区域学术机构联盟的优势,共同加强翻译。作为CTSA联盟的成员,OCTRI将为解决生物医学问题的共同努力贡献独特的专业知识和资源。俄勒冈州健康与科学大学及其合作机构凯撒永久健康研究中心已承诺强有力的领导支持和实质性的机构承诺OCTRI的持续使命。
公共卫生相关性(由申请人提供):OCTRI将对OHSU和KPCHR的临床和转化研究产生重大影响,并将增加其对生物医学发现的贡献。作为俄勒冈州唯一的学术医疗中心,OHSU有一个独特的机会,以促进区域范围内的转化研究增长。通过参与CTSA联盟,OCTRI将提高国家研究生产力。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ERIC S. ORWOLL其他文献
ERIC S. ORWOLL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ERIC S. ORWOLL', 18)}}的其他基金
Osteoporotic Fractures in Men (MrOS) - Portland
男性骨质疏松性骨折 (MrOS) - 波特兰
- 批准号:
8436051 - 财政年份:2013
- 资助金额:
$ 369.18万 - 项目类别:
Osteoporotic Fractures in Men (MrOS) - Portland
男性骨质疏松性骨折 (MrOS) - 波特兰
- 批准号:
9921179 - 财政年份:2013
- 资助金额:
$ 369.18万 - 项目类别:
Osteoporotic Fractures in Men (MrOS) - Portland
男性骨质疏松性骨折 (MrOS) - 波特兰
- 批准号:
9041473 - 财政年份:2013
- 资助金额:
$ 369.18万 - 项目类别:
Osteoporotic Fractures in Men (MrOS) - Portland
男性骨质疏松性骨折 (MrOS) - 波特兰
- 批准号:
8897222 - 财政年份:2013
- 资助金额:
$ 369.18万 - 项目类别:
相似海外基金
Oregon Clinical and Translational Research Institute TL1 Program
俄勒冈临床和转化研究所 TL1 项目
- 批准号:
9514380 - 财政年份:2017
- 资助金额:
$ 369.18万 - 项目类别:
Oregon Clinical and Translational Research Institute KL2 Program
俄勒冈临床和转化研究所 KL2 项目
- 批准号:
10197248 - 财政年份:2017
- 资助金额:
$ 369.18万 - 项目类别:
Oregon Clinical and Translational Research Institute Quality Assurance and Quality Control Project
俄勒冈临床和转化研究所质量保证和质量控制项目
- 批准号:
10158949 - 财政年份:2017
- 资助金额:
$ 369.18万 - 项目类别:
Oregon Clinical and Translational Research Institute
俄勒冈临床和转化研究所
- 批准号:
10198068 - 财政年份:2017
- 资助金额:
$ 369.18万 - 项目类别:
Oregon Clinical and Translational Research Institute
俄勒冈临床和转化研究所
- 批准号:
10693308 - 财政年份:2017
- 资助金额:
$ 369.18万 - 项目类别:
Oregon Clinical and Translational Research Institute
俄勒冈临床和转化研究所
- 批准号:
9514362 - 财政年份:2017
- 资助金额:
$ 369.18万 - 项目类别:
Oregon Clinical and Translational Research Institute - The National COVID Cohort Collaborative (N3C)
俄勒冈州临床和转化研究所 - 国家新冠肺炎队列协作组织 (N3C)
- 批准号:
10179888 - 财政年份:2017
- 资助金额:
$ 369.18万 - 项目类别:
Oregon Clinical and Translational Research Institute TL1 Program
俄勒冈临床和转化研究所 TL1 项目
- 批准号:
10197247 - 财政年份:2017
- 资助金额:
$ 369.18万 - 项目类别:
Oregon Clinical and Translational Research Institute - Evaluation of OCTRI's Response to COVID-19
俄勒冈临床和转化研究所 - OCTRI 对 COVID-19 响应的评估
- 批准号:
10158990 - 财政年份:2017
- 资助金额:
$ 369.18万 - 项目类别:
Oregon Clinical and Translational Research Institute
俄勒冈临床和转化研究所
- 批准号:
10675189 - 财政年份:2017
- 资助金额:
$ 369.18万 - 项目类别: